Authors


David Almeida, MD, MBA, PhD

Latest:

Two Faricimab Patient Cases from the Real-world in Neovascular AMD

Dr David Almeida shares two cases of neovascular AMD from his practice, one treatment-naïve and one previously treated, and presents his findings after switching them to faricimab.


Lorcan Butler, BSc (Hons), MCOptom, Prof Cert Paed Eye Care

Latest:

A field guide to optic disc drusen

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.


Vasant Raman, MS, FRCS(Glasg)

Latest:

Making the case for nurses to inject dexamethasone implants

Safety data on non-clinician-led services have shown a low complication rate


Leo P. Semes, OD, FAAO

Latest:

The significance of imaging and treatment in lattice retinal degeneration

Prompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.


Ben Shaberman

Latest:

Gene therapy: Where the action is for retinal diseases

Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.


Jeremiah Brown Jr, MD

Latest:

New dawn of GA management requires renewed attention to imaging

It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).


Marco Zarbin, MD, PhD, FACS

Latest:

Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trials in nAMD

Dr Marco Zarbin presents his talk from the 2023 ASRS annual meeting, where he explores the impact of disease activity criteria on drug durability estimations in clinical trials and includes a comparative analysis across multiple clinical trials in neovascular AMD (age-related macular degeneration).


David A. Goldman, MD

Latest:

Ultra-widefield imaging can enhance efficiency for practices

Physicians can discover, diagnose, document, treat diseases that might go undetected


Pouya Dayani, MD

Latest:

Noninfectious uveitis: Meeting the challenge

Chronic cases can be difficult for retina specialists; treatment is satisfying.


Sunil Mamtora, MD

Latest:

Achieving high-definition slit lamp imaging via smartphone mirroring

This affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching and reference purposes.


Brendan Girschek, MD, FRCSC, FACS

Latest:

Satellite clinics and other strategies to enhance rural ophthalmology 

Proactive communication and leveraging advanced, yet reliable, technologies  to maximize efficiency are essential pillars of success.


Marta Stevanovic, MD, MSc

Latest:

The future of retina care

Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.


Winston Posvar, OD, MS, FAAO

Latest:

Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disorders

The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.


Robert P. Finger, MD, PhD

Latest:

Investigating the quality of real-world evidence in retinal disease

Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.


Andrew Pucker, OD, MS, PhD, FAAO

Latest:

Using virtual reality mobility testing as a standardized clinical end point in inherited retinal disorders

The use of VR mazes hold an intrinsic advantage compared with physical mazes in the ability to control conditions and test various patterns with reliability, participant safety, and repeatability.


Mark R. Barakat, MD

Latest:

Precision medicine in diabetic macular edema: Expert consensus on the efficacy and safety of the 0.19-mg fluocinolone acetonide implant

Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.


Mark Michels, MD

Latest:

Dexamethasone rebuttal: Who should perform intravitreal injections?

In response to a previously published article, three ophthalmologists present their views on intravitreal pharmacotherapy injections.



Grace Koennecke

Latest:

Avirmax Biopharma prepares for IND-enabling study of ABI-201

ABI-201 aims to prevent dry AMD and other retinal disorders in patients.



Ashvini Reddy, MD

Latest:

Sustained drug delivery in ophthalmology

Current options, challenges in developing novel therapies.


Paul Hahn, MD, PhD

Latest:

Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy

A retina specialist shares his presentation from the 2023 ASRS Annual Meeting, which describes a study comparing the efficacy of 2 FDA-approved treatments for geographic atrophy based on an anchored matching-adjusted indirect comparison of phase 3 trial findings.


Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth

Latest:

Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.


Christina Y. Weng, MD, MBA

Latest:

The power of home monitoring

How modern tools may lead to customized AMD treatment plans


Kassi Jackson

Latest:

FDA issues CRL for aflibercept 8 mg from Regeneron Pharmaceuticals

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”


Aleksandra Rachitskaya, MD

Latest:

Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.


Varun Chaudhary, MD, FRCS(C)

Latest:

Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD

Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.


Roche

Latest:

UNCOVERING HIDDEN PREDATORS IN DISEASE

This article is produced by Roche for healthcare professionals and is not intended to provide medical advice and/or treatment guidance. This website is not country-specific and therefore may contain information which is not applicable to your country.


Theodore Leng, MD, MS

Latest:

Natural language processing helps ophthalmologists access data, improves data curation

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.


Sheri Rowen, MD, FACS

Latest:

Latest tech trends to benefit patients with AMD

Technology brings new tools to those with low vision caused by AMD

© 2025 MJH Life Sciences

All rights reserved.